LONDON, March 29 (Reuters) - GlaxoSmithKline shares gained on Wednesday as lack of news about U.S. approval of a generic copy of its blockbuster inhaled lung drug Advair buoyed speculation that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback